CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on the development of novel, proprietary therapeutics based on
hypoxia-inducible factor biology and the commercialization of these
products for patients with kidney disease, today announced that John P.
Butler, President and Chief Executive Officer, will present at the
annual UBS Global Healthcare Conference on Monday, May 19, at 2:30 p.m.
Eastern Time. The conference will take place at The Sheraton Hotel in
New York City.
A live audio webcast of the presentation will be available on the
Company's website at http://ir.akebia.com/events.cfm.
An archived presentation will be available for 90 days.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the
development of novel proprietary therapeutics based on hypoxia-inducible
factor (HIF) biology and the commercialization of these products for
patients with kidney disease. Akebia's lead product candidate, AKB-6548,
is in a Phase 2b clinical trial in patients with anemia secondary to
chronic kidney disease who are not dependent on dialysis. AKB-6548 is
being developed as a once-daily, oral therapy to inhibit
hypoxia-inducible factor prolyl hydroxylase, which is expected to
stabilize and increase levels of HIFα and improve the production of
hemoglobin and red blood cells.
Source: Akebia Therapeutics, Inc.
Investors:
Argot Partners, LLC
David Pitts,
+1-212-600-1902
david@argotpartners.com
or
Susan
Kim, +1-212-203-4433
susan@argotpartners.com
or
Media:
Feinstein
Kean Healthcare
Liz Falcone, +1-617-761-6727
liz.falcone@fkhealth.com
Source: Akebia Therapeutics, Inc.
News Provided by Acquire Media